Laura Espada Castro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Laura Espada Castro has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Audrey K. Cook
Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX
1 shared publication Carlo Cantile
University of Pisa Department of Veterinary Sciences Pisa
1 shared publicationDiego Daniel Miceli
Endocrinology Unit, School of Veterinary Medicine, University of Buenos Aires, Faculty of Veterinary Sciences , Buenos Aires
1 shared publicationEdward C. Feldman
School of Veterinary Medicine, University of California Department of Medicine and Epidemiology Davis, California
1 shared publication- Ezio Bianchi
Department of Veterinary Science, University of Parma, 43126 Parma, Italy
1 shared publication - Federico Fracassi
Department of Veterinary Medical Sciences, University of Bologna, Ozzano dell’Emilia, Italy
1 shared publication
Latest Publications
- Open Access
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (2) , 578-585
Clinical features of muscle stiffness in 37 dogs with concurrent naturally occurring hypercortisolism
Background: Severe muscle stiffness (SMS) in dogs with hypercortisolism (HC) is uncommon. Objectives: To evaluate signalment, presentation, treatments, and long-term outcomes of dogs with concurrent HC and SMS. Animals: Thirty-seven dogs. Methods: Medical records of dogs with HC and concurrent SMS were recruited from 10 institutions. Clinical information, test results, therapeutic responses, and survival times were reviewed. Results: All 37 dogs with HC and SMS had pituitary-dependent hypercortisolism (PDH); 36/37 weighed <20 kg. Signs and test results were typical of PDH aside from SMS, initially diagnosed in all 4 limbs in 9, pelvic limbs of 22, and thoracic limbs of 6 dogs. Hypercortisolism and SMS were diagnosed together in 3 dogs; HC 1-36 months before SMS in 23; SMS 1-12 months before HC in 11. Mitotane or trilostane, given to control HC in 36/37 dogs, improved or resolved HC signs in 28; SMS did not resolve, remaining static or worsening in 31/36 dogs, mildly improving in 5/19 dogs given additional therapies. Progression of SMS included additional limbs in 10 dogs and the masticatory muscles of 2. The median survival time from diagnosis of SMS was 965 days (range, 8-1188). Conclusions and Clinical Importance: Concurrent SMS and HC is uncommon, possibly affecting only dogs with PDH. Development of SMS might occur before or after diagnosis of HC. Apart from SMS, the clinical picture and survival time of these dogs seem indistinguishable from those of dogs with HC in general. However, while muscle weakness usually resolves with HC treatment SMS does not.
- 1 March 2023
- Published by Oxford University Press (OUP) in Journal of Veterinary Internal Medicine
- Vol. 37 (2) , 578-585
Open AccessClinical features of muscle stiffness in 37 dogs with concurrent naturally occurring hypercortisolism
Background: Severe muscle stiffness (SMS) in dogs with hypercortisolism (HC) is uncommon. Objectives: To evaluate signalment, presentation, treatments, and long-term outcomes of dogs with concurrent HC and SMS. Animals: Thirty-seven dogs. Methods: Medical records of dogs with HC and concurrent SMS were recruited from 10 institutions. Clinical information, test results, therapeutic responses, and survival times were reviewed. Results: All 37 dogs with HC and SMS had pituitary-dependent hypercortisolism (PDH); 36/37 weighed <20 kg. Signs and test results were typical of PDH aside from SMS, initially diagnosed in all 4 limbs in 9, pelvic limbs of 22, and thoracic limbs of 6 dogs. Hypercortisolism and SMS were diagnosed together in 3 dogs; HC 1-36 months before SMS in 23; SMS 1-12 months before HC in 11. Mitotane or trilostane, given to control HC in 36/37 dogs, improved or resolved HC signs in 28; SMS did not resolve, remaining static or worsening in 31/36 dogs, mildly improving in 5/19 dogs given additional therapies. Progression of SMS included additional limbs in 10 dogs and the masticatory muscles of 2. The median survival time from diagnosis of SMS was 965 days (range, 8-1188). Conclusions and Clinical Importance: Concurrent SMS and HC is uncommon, possibly affecting only dogs with PDH. Development of SMS might occur before or after diagnosis of HC. Apart from SMS, the clinical picture and survival time of these dogs seem indistinguishable from those of dogs with HC in general. However, while muscle weakness usually resolves with HC treatment SMS does not.